Dr Robert Klaassen, Professor, Department of Pediatrics, Division of Hematology/Oncology
University of Ottawa, Children’s Hospital of Eastern Ontario
The Thalassemia Foundation of Canada is pleased to announce the release of the Winter 2014 newsletter. Click here to view the newsletter.
ApoPharma Announces Health Canada Approval of Ferriprox (deferiprone)
TORONTO, Feb. 17, 2015 /CNW/ - ApoPharma Inc., today announced that Health Canada has granted approval of Ferriprox (deferiprone), an oral iron chelator for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Click here to read the press release.
Article on IV access for thalassemia and sickle cell patients.
Published in the Pediatric Hematology/Oncology Nurses Association Newsletter. Written by Kathy Grouchy, RN at BC Children’s Hospital. read more
MPP Introduces Bill to Improve Sickle Cell and Thalassemia Care in Ontario
TORONTO – On Thursday March 10th, 2011, MPP Mike Colle introduced a private member’s bill, Bill 165, Sickle Cell and Thalassemia Care Ontario Act, to establish a provincial body called Sickle Cell and Thalassemia Care Ontario. The Bill is calling for a provincial strategy to develop comprehensive coordinated care, promote awareness, and advocate for individuals living with Sickle Cell and Thalassemia across Ontario. read more
Liberals Champion Action on Sickle Cell Disease and Thalassemic Disorders
OTTAWA – In a display of solidarity with Canadians living with rare genetic blood disorders, Dr. Kirsty Duncan tabled her Private Member’s Bill (Bill C-605) on December 13, 2010 calling on the government to create a comprehensive National Strategy for Sickle Cell Disease and Thalassemic Disorders. read more